Business Context and Reporting Period
This Form 8-K Current Report was filed by Neoleukin Therapeutics, Inc. (NLTX) on September 22, 2023. The report details a material modification to the rights of security holders involving a reverse stock split approved by stockholders on June 8, 2023, and implemented by the Board of Directors on August 30, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: A one-for-five reverse stock split of the Company's common stock was implemented, effective at 12:01 am Eastern time on September 25, 2023.
- Share Count Reduction: Outstanding shares decreased from approximately 44,026,429 immediately prior to the split to approximately 8,805,285 shares post-split.
- Authorized Shares: The number of authorized common shares was reduced from 100,000,000 to 20,000,000.
- Trading Adjustments: Common stock began trading on a split-adjusted basis under a new CUSIP number (64049K 203) on September 25, 2023.
- Fractional Shares: No fractional shares were issued; stockholders received cash payments in lieu of fractional shares.
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options, pre-funded warrants, and shares reserved under equity incentive plans.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management outlook, or specific risk factors beyond the standard disclosure that the description of the Amendment is qualified by the full text of the Amendment filed as Exhibit 3.1. The primary purpose of the split was to adjust the capital structure, with no change to stockholder ownership percentages (except for fractional share cash-outs) or voting rights.
Investor Verification Checklist
- Verify the new CUSIP number (64049K 203) for trading purposes effective September 25, 2023.
- Confirm the adjusted number of shares held and any cash received for fractional shares.
- Review the adjusted exercise prices and share quantities for any outstanding stock options or warrants.
- Check the updated authorized share count of 20,000,000 in the Certificate of Incorporation.